乳酸脱氢酶是临床区域淋巴结阳性前列腺癌的血清预后因素。

Lactate Dehydrogenase Is a Serum Prognostic Factor in Clinically Regional Lymph Node-positive Prostate Cancer.

作者信息

Blas Leandro, Shiota Masaki, Yamada Shigetomo, Ieiri Kosuke, Nagakawa Shohei, Tsukahara Shigehiro, Matsumoto Takashi, Kashiwagi Eiji, Takeuchi Ario, Inokuchi Junichi, Shiga Ken-Ichiro, Yokomizo Akira, Eto Masatoshi

机构信息

Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

出版信息

Anticancer Res. 2021 Aug;41(8):3885-3889. doi: 10.21873/anticanres.15183.

DOI:10.21873/anticanres.15183

PMID:34281850

Abstract

BACKGROUND/AIM: Currently, there is no established prognostic serum parameter except PSA in clinically regional lymph node-positive prostate cancer. The aim of this study was to identify serum prognostic factors in clinically regional lymph node-positive prostate cancer.

PATIENTS AND METHODS

Patients diagnosed with regional lymph node-positive prostate cancer between 2008 and 2017 were included. The prognostic value of serum parameters for progression-free survival (PFS) and overall survival (OS) was investigated.

RESULTS

Univariate and multivariate analyses showed a statistically significant increased hazard risk for PFS and OS for men with lactate dehydrogenase (LDH) ≥230 IU/l at diagnosis. PFS at 5 years for patients with high and low LDH levels were 69.9% (95% CI=56.8-79.8%) and 18.9% (95% CI=1.23-53.2%), respectively (p=0.003). OS at 5 years for low and high LDH levels were 89.2% (95% CI=78.6-94.7%) and 46.3 (95% CI=11.2-76.2%), respectively (p=0.006).

CONCLUSION

This study shows that LDH is an independent predictor of PFS and OS in patients with regional lymph node metastatic prostate cancer.

摘要

背景/目的：目前，在临床区域淋巴结阳性前列腺癌中，除前列腺特异性抗原（PSA）外，尚无已确立的血清预后参数。本研究的目的是确定临床区域淋巴结阳性前列腺癌的血清预后因素。

患者与方法

纳入2008年至2017年间被诊断为区域淋巴结阳性前列腺癌的患者。研究了血清参数对无进展生存期（PFS）和总生存期（OS）的预后价值。

结果

单因素和多因素分析显示，诊断时乳酸脱氢酶（LDH）≥230 IU/L的男性，其PFS和OS的危险风险在统计学上显著增加。LDH水平高和低的患者5年PFS分别为69.9%（95%CI=56.8-79.8%）和18.9%（95%CI=1.23-53.2%）（p=0.003）。LDH水平低和高的患者5年OS分别为89.2%（95%CI=78.6-94.7%）和46.3%（95%CI=11.2-76.2%）（p=0.006）。